This article is for educational and research purposes only. Nothing here constitutes medical advice. Consult a licensed healthcare provider before using any peptide.
What Is Selank?
Selank is a synthetic heptapeptide developed at the Institute of Molecular Genetics of the Russian Academy of Sciences — the same lab that created Semax. It is based on the naturally occurring immunomodulatory peptide tuftsin (threonine-lysine-proline-arginine), with an added Pro-Gly-Pro C-terminal sequence for metabolic stability. Like Semax, Selank has been approved in Russia as a prescription anxiolytic and nootropic since the early 2000s.
While Semax is primarily characterized as a cognitive enhancer and stimulant-type nootropic, Selank occupies the complementary role of an anxiolytic nootropic — reducing anxiety and promoting calm focus without the sedation or cognitive impairment associated with benzodiazepines.
Mechanism of Action
Selank's anxiolytic and nootropic effects arise from its influence on multiple neurotransmitter systems:
- GABAergic modulation: Selank enhances the inhibitory effects of GABA, acting as an allosteric modulator at GABA-A receptors. Unlike benzodiazepines, which directly potentiate GABA signaling, Selank appears to modulate GABA sensitivity more gently, producing anxiolysis without significant sedation or muscle relaxation.
- Serotonin metabolism: Increases the expression of the rate-limiting enzyme tryptophan hydroxylase and modulates serotonin receptor expression, particularly 5-HT1A receptors associated with anxiety regulation.
- BDNF and enkephalin effects: Like Semax, Selank increases BDNF expression. It also modulates enkephalin levels — endogenous opioid peptides involved in mood regulation and stress response — without activating classical opioid receptor pathways associated with dependence.
- Immune modulation: As a tuftsin analog, Selank retains immunomodulatory properties, including regulation of IL-6 and TNF-alpha cytokine balance, which may contribute to its effects on neuroinflammation-related mood disturbances.
Clinical Evidence
Russian clinical studies have demonstrated Selank's efficacy for generalized anxiety disorder (GAD), with effects comparable to medazepam (a benzodiazepine) but without sedation, cognitive impairment, or dependence liability. In a comparative trial, patients with GAD receiving intranasal Selank showed significant reductions in anxiety scores (Hamilton Anxiety Rating Scale) over 14 days, with effects persisting after discontinuation.
Additional studies have reported improved cognitive performance under stress, enhanced memory consolidation, and normalization of gene expression patterns associated with anxiety in animal models. EEG studies show Selank increases alpha-wave activity — associated with relaxed alertness — while maintaining normal beta-wave patterns associated with cognitive engagement.
Dosing and Administration
- Standard formulation: 0.15% intranasal solution
- Typical dose: 250-500 mcg per day, split into 2-3 intranasal administrations
- N-Acetyl Selank: A modified version with reportedly enhanced bioavailability and anxiolytic potency
- Cycle length: 14-21 day cycles are standard, with breaks to prevent potential tolerance
The Bottom Line
Selank occupies a unique position as an anxiolytic that enhances rather than impairs cognitive function. Its GABA-modulating mechanism provides anxiety reduction without sedation, while its BDNF and serotonergic effects support mood and neuroplasticity. The clinical evidence from Russian studies is promising, though Western-standard randomized controlled trials are lacking. Selank is not approved for any indication outside of Russia and Ukraine.